Does taking a combined oral contraceptive pill (estrogen‑progestin) during early pregnancy increase the risk of congenital heart disease in the fetus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, taking oral contraceptive pills during early pregnancy does not cause congenital heart disease in the fetus

Based on the highest quality evidence available, inadvertent oral contraceptive use during early pregnancy does not increase the risk of congenital heart disease (CHD) in offspring. The most comprehensive and recent study addressing this specific question found no meaningful association between maternal contraceptive pill use and CHD.

Evidence Analysis

The National Birth Defects Prevention Study 1, a large multisite case-control study of 9,986 infants with birth defects and 4,000 controls, found no association between oral contraceptive use during the first 3 months of pregnancy and the vast majority of congenital malformations, including most types of CHD. While this study did identify associations with hypoplastic left heart syndrome (OR 2.3) and gastroschisis (OR 1.8), the authors explicitly stated these should be interpreted as hypotheses requiring further evaluation, particularly given that 32 different birth defects were assessed (raising concerns about multiple comparisons). The study concluded that "women who use OCs during early pregnancy have no increased risk for most types of major congenital malformations."

Supporting Evidence

Multiple earlier studies corroborate these findings:

  • A Finnish study of 406 CHD cases and 756 controls 2 found that maternal contraceptive pill use was not associated with increased risk of congenital heart disease when adjusted for confounding factors

  • A Hungarian prospective study of 24,732 pregnancies 3 found that oral contraceptive use did not influence the frequency of CHD (0.9% overall incidence), though alcohol consumption, smoking, and maternal age did show associations

  • A 1979 Massachusetts study 4 showed only a small positive association (prevalence ratio 1.5) between estrogen/progesterone exposure and cardiac malformation, but no association was evident between hormones and any specific class of cardiac defect, casting doubt on any causal relationship

Important Caveats

Distinguish Between Two Clinical Scenarios:

  1. Inadvertent OCP use during early pregnancy (the question at hand): Not associated with CHD risk
  2. OCP use in women WITH congenital heart disease (different question): Requires careful selection based on thrombotic risk and cardiac function 5, 6

What Actually Increases CHD Risk

The most recent systematic review and meta-analysis 7 identified the true maternal risk factors for CHD:

  • Pre-pregnancy diabetes (OR 2.91)
  • Maternal obesity (OR 1.23)
  • Active smoking (OR 1.28)
  • Passive smoking (OR 2.67)
  • Chronic hypertension (OR 1.39)

Oral contraceptive use is notably absent from this comprehensive 2025 analysis of maternal CHD risk factors.

Clinical Implications

When a woman presents having taken oral contraceptives during early pregnancy before realizing she was pregnant:

  • Reassure her that this exposure does not meaningfully increase CHD risk
  • Focus counseling on actual teratogenic risks (if any exist with her specific medication regimen)
  • Direct attention to modifiable risk factors that DO matter: smoking cessation, glycemic control, blood pressure management
  • Standard prenatal care and fetal cardiac screening based on other risk factors is appropriate

The guidelines provided 8, 9 address contraceptive safety in women with cardiovascular conditions, not teratogenic effects of contraceptives—these are separate clinical questions that should not be conflated.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.